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ABBREVIATIONS AND ACRONYMS: 
AF = Atrial fibrillation   TMPG =Transmitral pressure gradient  
AMC = Aortomitral curtain    TMVR= Transcatheter MV replacement  
AR = Aortic regurgitation   TTE =   Transthoracic echocardiography  
AS = Aortic stenosis     TEE =  Transesophageal echocardiography 
CAD=  Coronary artery disease   VHD = Valvular heart disease   
CKD = Chronic kidney disease    VTI =   Velocity time integral   
CT = Computed tomography    2D =    Two-dimensional  
CVD = Cardiovascular disease   3D =    Three-dimensional 
CW= Continuous wave    
DMS=  Degenerative mitral stenosis   
ESRD = End stage renal disease 
HTN=  Hypertension 
LA = Left atrium / atrial 
LV = Left ventricle / ventricular 
LVOT = Left ventricular outflow tract 
MAC = Mitral annular calcification  
MR = Mitral regurgitation 
MS = Mitral stenosis 
MV = Mitral valve 
MVA = Mitral valve area 
PA = Pulmonary artery/arterial 
PHT = Pressure half time 
PISA = Proximal isovelocity surface area 
PW=   Pulse Wave 
RMS = Rheumatic mitral stenosis  
RVOT = Right ventricular outflow tract 
TAVR = Transcatheter aortic valve replacement 
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ABSTRACT: 
 Degenerative mitral stenosis (DMS) is characterized by decreased mitral valve (MV) orifice area 
and increased transmitral pressure gradient (TMPG) due to chronic non-inflammatory degeneration and 
subsequent calcification of the fibrous mitral annulus and the MV leaflets. The ‘true’ prevalence of DMS 
in the general population is not well known. DMS predominantly affects elderly individuals, many of 
whom have multiple other comorbidities. Transcatheter MV replacement techniques, although their 
long-term outcomes are to be tested, have been gaining popularity and may emerge as an optimal 
treatment options for patients with DMS.  
 Echocardiography is the primary imaging modality for evaluation of DMS and related 
hemodynamic abnormalities such as increased TMPG and PA pressure. Classic echocardiographic 
techniques used for evaluation of MS (PHT, PISA, Continuity equation, MVA planimetry) lack validation 
for DMS. Direct planimetry with 3D echocardiography and color flow Doppler is a reasonable technique 
for determining MVA in DMS. Cardiac computed tomography is an essential tool for planning potential 
interventions or surgeries for DMS.  
 This article reviews the current concepts on mitral annular calcification and its role in DMS. We 
then discuss the epidemiology, natural history, differential diagnosis, mechanisms and 
echocardiographic assessment of DMS. 
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 “To raise new questions, new possibilities, to regard old problems from a new angle require 
creative imagination and marks real advance in science.” Albert Einstein1 
OVERVIEW AND BACKGROUND  
Mitral stenosis (MS) is characterized by reduced valve orifice area and increased resistance to 
diastolic transmitral flow due to pathological changes in the structure and function of the mitral valve 
(MV). This process leads to a rise in the left atrial (LA) and pulmonary arterial (PA) pressures and 
eventually a reduction in cardiac output.2 Rheumatic fever is the predominant cause of MS worldwide, 
although its frequency has significantly declined in the developed countries.3  
The main pathological changes observed in rheumatic MS (RMS) are commissural fusion, 
thickening at the leaflet tips, chordal shortening and restricted mobility of the posterior MV leaflet (with 
preserved mobility of the anterior MV leaflet in earlier stages).4 Historically, RMS has been extensively 
studied and this has led to broadened understanding of this disease. Several factors make RMS relatively 
easily recognizable in clinical practice. These include presentation at younger ages (symptoms are less 
likely to be confused with comorbidities), pathognomonic physical exam findings (opening snap with 
diastolic rumble, though it may not be heard in severe RMS) and  easy recognition with 
echocardiography.  
Contrary to RMS, non-rheumatic causes of MS, such as degenerative MS (DMS) have been 
considered to be rare. And they have received limited attention from clinicians and scientist up until 
recently. Significant improvements in longevity and aging of the general population have increased the 
prevalence of degenerative valvular heart disease (VHD). In contrast to the extensive knowledge on the 
natural history of degenerative aortic stenosis (AS), DMS remains a relatively ill-defined disease process. 
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In the literature, ‘calcific MS’ and ‘MS due to mitral annular calcification (MAC)’ have also been 
used to refer to DMS. DMS is usually characterized by MAC, and thickening and calcification of the MV 
leaflets. Contrary to RMS, DMS predominantly affects the base of the leaflets while the leaflets tips and 
commissures are usually spared.4 The narrowest part of the orifice is often at the base of the leaflets 
instead of the tips. Recognition and diagnosis of DMS have been a challenge for clinicians mainly due to 
lack of validated echocardiographic parameters to quantify the degree of MS and the presentation of 
the disease usually in elderly patients who commonly have other symptomatic cardiac and non-cardiac 
conditions. Treatment of DMS has also been a challenge for several reasons such as the unavailability of 
medical therapies to prevent progression and delay the need for interventions and no benefit from 
percutaneous mitral balloon valvuloplasty or surgical commissurotomy. Moreover, surgical MV 
replacement have not been extensively used in this disease because of technical difficulties and high risk 
for complications of surgery in the presence of MAC and  poor surgical candidacy of patients due to 
advanced age, debility and/or presence of multiple comorbidities.5–7 Some innovative surgical 
techniques such as supra-annular insertion of a prosthesis or the use of a felt patch around the orifice as 
an anchor for prosthesis have been reported.8,9 More recently, transcatheter MV replacement (TMVR) 
with “off-label” use of transchateter aortic valve replacement (TAVR) devices in DMS have been 
described (Figure 1).10 
Improvements in echocardiographic evaluation of DMS is essential for patient selection, timing 
of interventions, imaging guidance during procedures and post-procedure follow up. The revolutionary 
changes in the management of degenerative AS in the recent decade remind us that, superior 
interventional or surgical outcomes can only be achieved with parallel improvement in imaging 
modalities.   
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The aim of this review is to provide a comprehensive and contemporary update on DMS with a 
special focus on mechanisms, epidemiology, natural history and echocardiographic evaluation of DMS. 
MITRAL VALVE ANATOMY 
 The MV apparatus consists of four key components: mitral annulus, MV leaflets, the chordae 
tendineae and papillary muscles. Abnormalities in any of these structures can lead to dysfunction of the 
MV. The mitral annulus is the anatomically ill-defined fibrous tissue at the juncture of the LA, left 
ventricle (LV) and MV leaflets. The mitral annulus resembles a kidney bean in two-dimensional (2D) 
images. In three-dimensional (3D) images, it has a saddle shape with anterior (aortic) and posterior 
aspects elevated compared to the medial and lateral (commissural) portions (Figure 2).11–13 This saddle 
shape of the annulus has been shown to reduce the mechanical stress exerted on the MV leaflets.14  In 
adults, 3D area of the mitral annulus is approximately 10 cm2 (range: 7 cm2 – 12 cm2).15 The mitral 
annular area may change 20% to 42% between systole and diastole.11  
 The MV has anterior and posterior leaflets with the coaptation line from an anterolateral to 
posteromedial direction. The surface area of the MV leaflets is approximately 50% larger than the mitral 
annular area. This is essential for prevention of mitral regurgitation (MR). The anterior MV leaflet is 
usually larger than the posterior MV leaflet and has a traphezoid shape. The posterior MV leaflet is 
crescentic shaped and occupies two thirds of the annular circumference.11  
Transthoracic echocardiography (TTE) is the primary imaging modality for evaluation of MV 
geometry, morphology and function. Transesophageal echocardiography (TEE), with the improved 
spatial resolution and lower rate of acoustic shadowing, provides a superior and more precise 
assessment of MV lesions.16  
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MITRAL ANNULAR CALCIFICATION 
MAC is a chronic degenerative non-inflammatory process involving the fibrous mitral annulus 
and resulting in its progressive calcification.17 MAC, by itself, does not cause any symptoms. Therefore, it 
is most commonly encountered as an incidental finding during evaluation of pulmonary diseases or 
other cardiovascular diseases (CVD).18 Nevertheless, MAC has several prognostic clinical implications and 
it has been associated with increased risk of atherosclerosis,19 coronary artery disease,20 ischemic 
stroke,21 atrial fibrillation (AF),22 conduction system disorders23 and mortality from CVD.24 
The prevalence of MAC varies depending on the characteristics of the population studied and 
the diagnostic imaging modality utilized. The prevalence of MAC (computed tomography [CT] detected) 
was reported as 9% in the Multiethnic-Study of Atherosclerosis, a community based study of adults, 
ages 45–84 years old, without apparent CVD.25 In elderly individuals (>65 years of age) its frequency 
increases to 42%.26 Risk factors for MAC include older age, female gender, white race, chronic kidney 
disease (CKD), hypertension, diabetes mellitus, LV hypertrophy, increased body mass index, cigarette 
smoking and increased level of systemic inflammation.25,27–29 Patients with CKD and particularly end-
stage renal disease (ESRD) tend to develop MAC at younger ages and with a more rapid rate of 
progression compared to individuals with normal renal function.24,30 The prevalence of MAC in dialyzed 
patients has been reported as 44% to 64%.31,32  
Multiple pathophysiologic mechanisms play a role in the development of MAC. These include 
abnormalities in calcium and phosphorus metabolism, increased hemodynamic stress on the MV and 
atherosclerosis. 17–19 Increased prevalence of MAC in patients with MV prolapse have been attributed to 
the annular trauma secondary to the excess tension caused by redundant hypermobile MV leaflets.33 A 
genetic contribution to the risk of MAC has also been described. A genome-wide association study 
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revealed an association between MAC and genetic polymorphisms near the pro-inflammatory gene 
IL1F9.34  
Echocardiographic Evaluation of Mitral Annular Calcification 
MAC is a common finding on echocardiography. There is no standardized echocardiographic 
definition of MAC or criteria to grade its severity. Parasternal long- and short-axes are the best views for 
detection of MAC, but it can also be visualized in apical views. On M-mode echocardiography, MAC is 
appreciated as an echo dense band beneath the posterior MV leaflet that moves in parallel with the LV 
posterior wall. On 2D echocardiography, it typically presents as a bright shelf-like irregular echodensity 
with associated acoustic shadowing at the angle of the posterior MV leaflet and atrio-ventricular groove 
(Figure 3).18  
In epidemiologic studies utilizing echocardiography, the severity of MAC was quantified based 
on either the maximal thickness of echodensity (>4 mm thickness defines severe MAC)35 or the extent of 
mitral annular involvement on parasternal short-axis view (focal calcification in the mitral annulus 
defines mild MAC and marked calcification involving more than half of the circumference of the mitral 
annulus or intrusion of LV inflow tract with calcification defines severe MAC).26  
Several limitations exist in the echocardiographic assessment of MAC. Echocardiography has 
relatively low specificity for distinguishing calcium from dense collagen25 and its quantification of 
calcium is limited to visual scoring which is associated with significant variability due to reflection and 
diffraction of ultrasound waves.36 In addition, the standard parasternal short-axis view, which is usually 
used to quantify the severity of MAC, does not visualize the anterior mitral annulus because it is not in 
the same plane with the posterior mitral annulus (Figure 3-B). This may result in missing the anterior 
annular calcification and underestimating the severity of MAC.32  
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Cardiac CT Evaluation of Mitral Annular Calcification   
CT is considered to be superior to echocardiography in demonstrating the location and extent of 
MAC.18 It can provide better distinction of calcification and more complete visualization of the mitral 
annulus (Figure 4). On CT, MAC is defined by an Agatston score (a standardized calcium quantification 
score on cardiac CT) > 0 at the LA and LV junction. Agatston score can also be used to quantify the 
severity of MAC, though there are no standardized cut-off values for grading.37 MAC is usually detected 
as an incidental finding on CT scans of the abdomen or chest. More detailed evaluation of MAC can be 
achieved with dedicated electrocardiography-gated CT scans. Use of intravenous contrast material 
during CT scan can provide better visualization of the MV leaflets and myocardium.38 Thus, CT with 
intravenous contrast can detect calcification of the MV leaflets and subvalvular apparatus and 
myocardial extension of calcification.38 Estimation of mitral annular area is crucial for success of 
percutaneous MV interventions and this information can be obtained with CT (Figure 4-B). Moreover, 
electrocardiography-gated contrast enhanced CT scan can provide reproducible estimates of the MV 
area (MVA) with use of a planimetry method. MVA obtained with CT-planimetry strongly correlates with 
the values obtained with cardiac catheterization (Gorlin formula)39 or TTE using pressure half time 
(PHT)39 or 2D planimetry methods.40 It should be noted that CT slightly overestimates MVA (by ~0.15 
cm2) compared to echocardiographic planimetry or cardiac catheterization.39 The superior imaging 
features makes CT an essential tool at the planning stage of potential interventions or surgeries for 
DMS.17 
Distribution of Calcification 
Epidemiologic studies utilizing M-mode or 2D echocardiography have traditionally suggested 
that, MAC predominantly affects the posterior annulus and involvement of the anterior annulus is 
extremely rare.41 Data from more recent studies utilizing multimodality imaging have demonstrated that 
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involvement of the anterior annulus is not as rare as it was previously thought. A recent retrospective 
study on patients ≥ 65 years of age assessed the frequency of calcium deposits in different segments of 
the mitral annulus using non-contrast CT scan images performed for other clinical indications. The 
authors observed isolated posterior annulus calcification in 33%, isolated anterior annulus calcification 
in 5%, and both the anterior and posterior annulus calcification in 11% of the patients.37 Detection of 
anterior MAC (Figure 4-A) carries significance in regards to risk of MS and presence of anterior MAC 
might be a better predictor of smaller MVA compared to posterior MAC.36   
Mitral Annular Calcification and Mitral Valve Function 
 Recent studies, particularly with the help of multimodality imaging, have broadened the general 
understanding of mitral annular function and the impact of MAC on MV function and efficiency. 
Normally, all the components of the MV (the leaflets, annulus and subvalvular apparatus) function as a 
unit. The mitral annulus is a very dynamic structure and its shape changes throughout the cardiac cycle. 
In early systole, normally functioning mitral annulus contracts, particularly along the antero-posterior 
diameter, and accentuates its saddle shape due to descent and folding along the intercommissural 
diameter. These motions contribute to early approximation, coaptation and sealing of the MV leaflets 
and reduction of annular area and leaflet stress.12,14,42 
 Pressman et al. evaluated the mitral annular function using 3D echocardiography in individuals 
with varying degrees of MAC and age- and sex-matched controls.12 The subjects were free of any other 
VHD. The study demonstrated that the behavior of the mitral annulus throughout the cardiac cycle was 
significantly different in patients with moderate and severe MAC compared to control subjects. MAC 
was found to be associated with impaired contraction of the annulus in systole and a mildly larger and 
flatter annulus throughout the cardiac cycle. The mild enlargement of the mitral annulus was mainly 
attributed to its decreased contraction during systole. Overall, the findings suggested that moderate and 
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severe MAC, by impairing annular dynamics, can cause inefficient blood flow through the LV. The results 
of the study also challenged the traditional assumption that mitral annular narrowing is the main cause 
of the increased pressure gradient across the MV in patients with MAC.  
 The calcification in the mitral annulus does not respect the annular boundaries and it usually 
extends into the LV myocardium, LA and/or onto the MV leaflets.43 Involvement of the MV leaflets 
appear to contribute to MS and valve dysfunction observed in patients with MAC. Movva et al. assessed 
the relationship of MAC with leaflet motion and trans-mitral pressure gradients (TMPG) in a cohort of 75 
patients with ESRD.32 The authors determined the degree of MS based on TMPG which was estimated 
using mitral inflow spectral Doppler. Sixty-four percent of the study participants were found to have 
some degree of MAC. Among the patients with MAC, 75% had moderate to severe calcification, 58% had 
extension of calcification more than halfway onto at least one of the leaflets and 62% had protrusion of 
calcification beyond the mitral annulus. None of the patients with mild MAC were found to have 
pressure gradient across the MV, while 58% of the patients with moderate and severe MAC did. MS was 
found to be significantly associated with the severity of calcification and extension of calcification 
beyond the mitral annulus or onto the MV leaflets. Extension of calcification more than halfway onto 
the MV leaflet(s) was the strongest predictor of restricted leaflet motion. In addition, presence of 
calcium in an annular segment was associated with a reduced opening angle of the attached leaflet 
segment.   
RADIOTHERAPY INDUCED MITRAL VALVE DISEASE 
 Radiotherapy induced MV disease is a form of VHD with distinct pathophysiologic and imaging 
features and it shares some common features with degenerative MV disease. A good grasp of some 
general features of this condition is crucial in approaching patients with suspected degenerative MV 
disease. 
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   Radiotherapy induced VHD is a dose-dependent late complication of radiation for thoracic 
malignancies such as lung cancer or Hodgkin’s disease. Clinically significant VHD manifest >20 years after 
exposure to radiation and predominantly affects left sided valves.44 Valvular regurgitation is more 
frequently seen with radiation induced VHD, although AS and MS have also been reported. The hallmark 
findings of radiation induced MS are severe MAC (predominantly the anterior annulus), thickening and 
calcification of the aortomitral curtain (AMC), anterior MV leaflet and aortic valve.4, 30 The poster MV 
leaflet has been reported to remain mobile in some cases. Radiation-induced MS typically also differs 
from RMS. It typically affects the base or mid-body of the MV leaflets and does not affect the 
subvalvular apparatus or cause commissural fusion.45 It should be kept in mind that restrictive 
cardiomyopathy may accompany radiation induced VHD in severe forms.38  
AORTOMITRAL CURTAIN AND MITRAL VALVE FUNCTION 
 The AMC is defined as the fibrous tissue between the anterior mitral annulus and aortic valve 
annulus at the level of left and non-coronary cusps. There is now growing evidence that the dynamics of 
aortic and mitral annuli are interdependent throughout the cardiac cycle and the mitral and aortic 
coupling is an essential component of the normal cardiac physiology. The AMC, as an anchor affecting 
the function of both valves, plays a critical role in mitral-aortic valvular coupling. The dynamic nature of 
the angle between aortic valve and MV appears to contribute to the blood flow through the LV outflow 
tract (LVOT).46 Structural abnormalities in the AMC appear to have prognostic consequences. In fact, a 
retrospective study on a patient population with radiation induced cardiac disease who underwent 
cardiothoracic surgery identified increased thickness of AMC as an independent predictor of mortality.47 
Two possible explanations for this association were as follows. The thicker AMC may reflect overall 
advanced CVD or it may signify a causative relationship between thickened AMC and adverse surgical 
outcomes. 
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The relationship between MAC and structure and function of the AMC has not been studied. A 
recent study reported the frequency of AMC calcification as 15.8% among AS patients who were 
referred for TAVR.48 These results suggest that AMC thickening and calcification may not be limited to 
the patients with radiation induced heart disease but can be seen as a part of age-related degenerative 
process. We need further research to determine the extent of AMC involvement in patients with 
anterior MAC and to explore the possible contribution of AMC calcification and dysfunction in DMS. 
DEFINING SEVERE MITRAL STENOSIS 
In simple terms, severe MS is defined as the degree of stenosis at which MS symptoms 
(exertional dyspnea and decreased exercise tolerance being the most common) would occur and an 
intervention for the MV would improve these symptoms.5 Worsening degrees of MS result in a cardiac 
output level which is subnormal at rest and fails to increase during exercise.  
The normal MVA at the tips is 4.0 to 5.0 cm2.  Individuals with an MVA >1.5 cm2 usually do not 
have any symptoms due to MS.49 The current VHD management guidelines define severe MS as a MVA 
of ≤1.5 cm2. This generally corresponds with a mean TMPG of 5 to 10 mmHg across the MV at a normal 
heart rate (Table 1).5 The current guidelines do not recommend indexing the valve area based on gender 
or body size. It remains unclear how to define severe MS based on MVA values determined by CT-
planimetry. An investigation by Lebcke et al suggested that a CT-determined MVA of 1.7 cm2 is the best 
cut-off to distinguish mild MS from moderate to severe MS.39  
The values for quantification of MS severity were defined based on research studies involving 
patients with RMS. These definitions have not been validated in patients with DMS. 
Another potential challenge exists in assessment of MVA in patients with DMS. It remains 
unclear whether it is reliable to use the same MVA threshold values in both RMS and DMS. Some 
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previous studies have suggested that same stenotic orifice area may lead to different gradients across 
the valve in RMS and DMS because of differences in the geometry of the orifice and mobility of the 
leaflets.50 Gilon et al., using 3D echocardiographic laser stereolitography, have tested the hypothesis 
that 3D geometry proximal to the stenotic orifice significantly impacts the pressure loss across a stenotic 
valve.51 The study revealed that for the same anatomic MVA, mobile dome shaped MV geometry (such 
as in RMS) is associated with larger effective orifice area and smaller TMPG when compared to funnel 
shaped or flat immobile MV geometry (such as in DMS). These results suggested that at a given 
anatomic orifice area DMS can result in more significant hemodynamic impact on the flow. The 
hemodynamic differences between distinct valve morphologies were attributed to the fact that a dome 
shaped stenosis would permit more gradual convergence of flow proximal and distal to the stenosis.  
EPIDEMIOLOGY OF DEGENERATIVE MITRAL STENOSIS 
 Because of lack of a standardized definition of DMS, there is a great variability among 
epidemiologic studies in terms of how DMS is defined and its severity is quantified. Some of the 
methods used to diagnose DMS were as follow: hearing a ‘MS’ murmur in the presence of MAC, 
elevated TMPG determined by echocardiography or MVA determined by different algorithms such as 
planimetry, PHT or continuity equation. The cut-off levels for these parameters also differed from study 
to study. Due to the variability among studies and the use of non-validated techniques (as will be 
discussed below), the results of epidemiologic studies should be interpreted with caution. Most 
epidemiologic studies on DMS are either single-center studies with relatively small patient numbers or 
date back to 3-4 decades ago. Therefore, our knowledge on the contemporary epidemiology and natural 
history of DMS is limited.  
 A prospective survey which was published in the early 2000’s and included 5,000 patients with 
moderate-to-severe native VHD from 25 different European countries reported the frequency of DMS as 
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12.5% among all MS cases.52 The proportion of patients with DMS was significantly higher in advanced 
age groups. For instance, DMS accounted for 60% of all MS cases in patients >80 years of age. In a 
retrospective study on a cohort of unselected individuals (n=4270) who were referred for outpatient 
echocardiograms, 0.5% of the individual were found to have severe MAC and increased pressure 
gradients across the MV at rest.41   
MAC shows significant association with MR. In a retrospective study, presence of MAC was 
associated with a 2-fold increased risk of MR.53 The epidemiologic characteristics of concomitant DMS 
and MR have not been defined. DMS show significant association with degenerative involvement of 
other valves. Iwataki et al. reported the frequency of severe DMS (defined as MVA <1.5 cm2 by 
continuity equation) as 24% among patients with degenerative AS.54 Another recent study assessed the 
frequency of MV pathologies detected with CT among 394 severe AS patients referred for TAVR.36 In this 
cohort, 50% of the subjects were found to have MAC. In addition, 32% of subjects with MAC were found 
to have a MVA < 2 cm2 based on MV planimetry with CT. Severe degenerative AS has also been 
associated with increased TMPG. Yong et al. reported the frequency of subjects with increased TMPG 
(invasively determined TMPG of ≥5 mm Hg) as 55% in a cohort of patients with severe degenerative AS 
who were referred for balloon aortic valvuloplasty.55 
NATURAL HISTORY OF DEGENERATIVE MITRAL STENOSIS 
 Pasca et al. have recently shed some light on the natural history of DMS.56 Their single-center 
study was conducted on a cohort of 1004 DMS patients with a mean follow-up period of 3.5±2.8 years. 
In the study, DMS was defined as increased mean TMPG (>2 mm Hg) in the presence of severe MAC 
without commissural fusion. MS grading was performed based on the mean pressure gradients 
estimated by echocardiography. In the cohort, 78% of the patients had mild MS, 14% moderate and 8% 
severe. DMS was associated with very poor survival with 1-, 5- and 10-year mortality rates of 32%, 53%, 
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75%, respectively. When compared to the US general population (similar age- and sex-distribution), 5-
year mortality was almost 3 times higher in patients with DMS (Figure 5). The predictors of poor survival 
in patients with DMS were; advanced age, AF, renal failure, other valvular abnormalities (AS, MR or 
tricuspid regurgitation), increased right sided filling pressures, low albumin and use of digoxin. Higher 
grade of DMS was a predictor of mortality in their multivariate analysis. Its effect did not remain 
significant in the comprehensive model, which included clinical biochemical, and pharmacologic data. 
These results suggest that DMS is a marker of poor survival. However, further research is needed to 
investigate whether DMS has a direct impact on mortality. 
 The data on natural course of progression of DMS is also limited. Tiyagi et al. assessed the 
characteristics of progression of DMS in a cohort of 254 patients. The authors observed that, in patients 
with DMS, TMPG progressively increases with a rate of 0.8±2.4 mm Hg per year.57 
ECHOCARDIOGRAPHIC QUANTIFICATION OF DEGENERATIVE MITRAL STENOSIS  
Reliable estimation of MVA and mean TMPG are the main components of echocardiographic 
assessment of MS. There exist several echocardiographic techniques for assessment of MVA and mean 
TMPG. Strengths, weaknesses and applicability of these techniques in patients with DMS are given in 
Table 2 and discussed below. The validity of these techniques has mainly been tested in patients with 
RMS. There have been no well-designed studies in patients with DMS comparing the echocardiography 
defined MVA and TMPG values with those obtained from invasive hemodynamic studies or surgically 
removed valves.  
Echocardiographic Warning Signs 
Since DMS is not a commonly encountered clinical entity, a high index of suspicion is essential 
for early diagnosis of this condition. Cardiologists and sonographers should be aware of 
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echocardiographic warning signs of DMS (Table 3). Presence of these warning signs should trigger 
detailed echocardiographic evaluation (including 3D) of the entire MV apparatus. It should be noted that 
in patients with DMS, calcification occurs at the base of the leaflets while the leaflet tips are usually 
spared. Thus, pliable and thin leaflet tips appearing on echocardiography images should not be 
interpreted as a finding against the presence of MS.   
Mitral Valve Area by Planimetry 
Direct planimetry is considered as the most reliable echocardiographic method to determine 
MVA in patients with RMS. 2D planimetry involves direct visualization of the MV leaflets in the 
parasternal short-axis view in mid-diastole and tracing of the inner rim of the orifice, including opened 
commissures, to calculate MVA.2 Direct planimetry requires careful scanning across the MV and 
optimum beam position and angulation to determine and intersect the limiting orifice which in RMS is 
usually at the tips of the leaflets. Averaging of several measurements is recommended in the presence 
of AF or heart rate variability. A major advantage of direct planimetry is that, unlike other 
echocardiographic methods to assess MS, planimetry is not affected by cardiac chamber compliance, 
flow conditions or other valvular abnormalities such as MR or aortic regurgitation (AR).16  Multiple 
studies in patients with RMS have confirmed that MVA determined by 2D direct planimetry strongly 
correlates with direct sizing during surgery and invasively derived MVA by Gorlin formula.58,59 3D 
echocardiography, which can provide simultaneous display of orthogonal views, can enhance accuracy 
of MVA measurements. Direct planimetry with 3D echocardiography is a reliable and reproducible 
method in RMS. And it was shown to be superior to 2D echocardiography in assessment of MVA in 
patients with RMS.60,61 3D echocardiography can be performed with both transthoracic and 
transesophageal echocardiographic techniques. 
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Planimetry of MVA with 2D echocardiography is challenging and unreliable in patients with 
DMS. The limiting orifice of mitral inflow in DMS is usually located at the base of MV leaflets. Thus, 
planimetry at the level of leaflet tips does not represent the true limiting orifice. Moreover, the acoustic 
shadowing from the calcification of the annulus and leaflets prevents 2D visualization of the orifice at 
the base.16 3D echocardiography (with TTE or TEE) have been suggested to overcome these limitations. 
It may provide more accurate quantification of limiting orifice in DMS due to its ability to demonstrate 
en-face views of the MV structure.30 3D echocardiography can also be helpful in confirming the absence 
of commissural fusion. Severe calcification and blooming artifact may represent a challenge for 
visualization of limiting orifice and leaflet tips in some cases. 
Chu et al. described a color-flow guided real time 3D echocardiographic planimetry method for 
determining the limiting mitral orifice in a cohort of 34 patients with suspected DMS.50 The investigators 
excluded patients with significant MR or AR and used MVA obtained by continuity equation with 
continuous wave (CW) Doppler as the independent standard of effective MVA. The study demonstrated 
that MV orifice area calculated by 3D echocardiography strongly correlates with the independent 
standard (continuity equation). Interestingly the stenotic orifice in DMS was found to have a tubular 
geometry which is different from doming pattern seen with RMS.  MVA calculation by 3D 
echocardiography has not been validated using invasive evaluations. 
In conclusion, planimetry with 3D echocardiography (particularly with TEE approach) is most 
useful echocardiographic modality to confirm diagnosis and quantify the orifice area in patients with 
DMS.  
Pressure Half Time Method 
The PHT refers to the time interval it takes for the TMPG to decay to the half of peak value 
observed in diastole.2 The PHT method for estimation of MVA is based on the concept that the duration 
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of pressure drop from LA to LV inversely correlates with the mitral orifice area.16 The PHT is calculated 
with CW Doppler of mitral inflow obtained from apical four chamber view. The significant correlation 
between PHT and invasively determined MVA was first described by Hatle et al. in 19 patients with MS.62 
Based on this correlation, an empiric formula of MVA=220/PHT was subsequently derived. The original 
report by Hatle et al. did not specify the etiology of MS in the patients included in their study. Later 
studies which specifically included RMS patients confirmed the association between PHT and invasively 
(with Gorlin formula) or surgically determined MVA in this patient population.59,63. PHT is easy to 
perform and less time consuming. 
The PHT method is dependent on the compliance of LV and LA. Decreased LV compliance, a 
cardinal finding of diastolic dysfunction, commonly coexist with severe MAC (seen in the older 
population). In the presence of decreased LV compliance PHT may shorten due to rapid equilibration of 
TMPG and this may result in overestimation of derived MVA.50,64 A study by Karp et al. compared the 
PHT-derived and Gorlin equation-derived MVA in individuals with normal and decreased LV 
compliance.65 In individuals with stiff LV (decreased LV compliance), the PHT method overestimated the 
invasively derived MVA by 72%. Overestimation was only 10% for individuals with normal LV 
compliance. 
PHT is inversely related to MVA, and directly to LA compliance and square root of peak 
transmitral gradient.64 Computer generated models of this relationship have shown that for a fixed MVA 
and a fixed initial LA pressure, decreasing LA compliance (or increasing stiffness) may shorten PHT and 
lead to overestimation of MVA by this method.64 Decreased LA compliance is an important cause of 
increased LA pressure and have been associated with poor prognosis in patients with RMS.66 Further 
research is needed on patients with DMS to investigate the characteristics of LA compliance and the 
impact of LA compliance on MV hemodynamics and PHT in this patient population. 
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The PHT is considered to be unreliable in patients with tachycardia or AF.2 Concomitant AR 
and/or AS may also shorten PHT by affecting LV filling time or compliance.67 Consistent with the 
limitations listed above, a retrospective study on patients with MS who underwent echocardiography 
and cardiac catheterization demonstrated that PHT method significantly overestimates MVA in patients 
age 65 years or older.68 Because of the high likelihood of inaccurate estimation of MVA, valve stenosis 
guidelines recommended against use of PHT in assessment of DMS.49  
Proximal Isovelocity Surface Area Method 
The proximal isovelocity surface area (PISA) method relies on the principal that flow converges 
and accelerates towards an orifice, and that results in formation of shells with increasing velocity and 
decreasing radius. And based on the low of conservation of mass, the flow rate through a stenotic MV 
must be equal to the flow rate at a given hemispheric shell.2 The PISA for MVA is obtained with color 
flow Doppler in apical four chamber view. The calculation of PISA requires the measurement of several 
different parameters: the aliasing velocity, radius of the convergence hemisphere, the peak mitral inflow 
velocity and the opening angle of the leaflets relative to flow direction.30 The PISA method for 
estimation of MVA has been validated in patients with RMS.69 The PISA method appears to have several 
advantages compared to the PHT method. It has been shown to be less or not affected by MR,69 AF,70 
AR,71 and changes in atrio-ventricular compliance.72 However the PISA method is technically difficult, 
more time consuming and susceptible to measurement errors.49 De Agustin et al. tested the validity of 
3D echocardiography PISA for estimation of MVA in patients with RMS.73 The study demonstrated that, 
compared to the traditional 2D PISA method, the novel 3D PISA method better correlates with the other 
reference techniques (planimetry and PHT) used to determine MVA.  
To our knowledge, there has been no study assessing the use of PISA method in patients with 
DMS. Its validity in this patient population has not been determined. The PISA method is particularly 
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challenging in evaluation of DMS because of difficulty of determining the location of flow limiting orifice 
and calculation of opening angle relative to the direction of flow.  
Continuity Equation Method 
 The continuity equation method relies on the law of conservation of mass. This method requires 
that, in the absence of valvular regurgitation or intra-cardiac shunting, the transmitral stroke volume is 
equal to the stroke volume obtained from right ventricular outflow tract (RVOT) or LVOT.2 Based on the 
Doppler-derived continuity equation, the MVA can be calculated with the following formula: 
MVA=Stroke Volume/Mitral Velocity Time Integral (VTI).49 Some studies have demonstrated that the 
MVA determined by continuity equation correlates with the values obtained from cardiac 
catheterization (by Gorlin formula) in patients with RMS (correlation coefficient of 0.64).63 The 
continuity equation was used as one of the reference methods to determine the MVA in the study by 
Chu et al. which tested the validity of planimetry by 3D echocardiography in patients with DMS.50 That 
study demonstrated a strong correlation with MVA values determined by Doppler-derived continuity 
equation and 3D planimetry.  
There are several limitations for use of continuity equation method for assessment MVA. 1) Like 
the PISA method, continuity equitation requires multiple independent measurements which make this 
test susceptible to manual measurement errors. 2) It is generally difficult to reliably obtain RVOT stroke 
volume because of poor acoustic windows. 3) The continuity equation for MVA becomes invalid in the 
setting of significant MR, AR (if LVOT stroke volume is used as reference) or pulmonary regurgitation (if 
RVOT stroke volume is used as reference). 4) AF or other irregular heart rhythms result in beat-to-beat 
variability in stroke volume and make continuity equation unreliable.49 
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 In conclusion, the continuity equation is not an ideal method for calculation of MVA in patients 
with DMS because of the possible impact of measurement errors and high prevalence of concomitant 
irregular heart rhythm or valvular regurgitation in this patient population.  
Doppler-derived Transmitral Pressure Gradient 
The TMPG is considered the main supportive criterion in the assessment of MS.49 The 
echocardiographic TMPG is obtained from apical 4-chamber view with use of CW Doppler and 
application of simplified Bernoulli equation (4 x [velocity]2). The peak Doppler velocity is used to 
calculate the peak TMPG, whereas the average of instantaneous gradients enveloped in the CW Doppler 
signal is used to calculate the mean TMPG.2 In order to obtain the maximum gradient, the Doppler beam 
needs to be aligned parallel to flow.16 The mean TMPG is considered to be a more reliable hemodynamic 
parameter because the peak TMPG is highly variable and more influenced by LA compliance and LV 
diastolic dysfunction.74 In patients with RMS, Doppler-derived mean TMPG values correlate well with 
invasive measurements obtained with trans-septal catheterization.75 Such validation studies are lacking 
for patients with DMS. A study by Hermann et al. utilized an in-vitro simulator and MV models and 
revealed a good correlation between Doppler-derived and invasively measured TMPG values in the 
presence of severe MAC, but the Doppler method slightly overestimated the pressure gradient.76 
In patients with AF, it is recommended to take the average of multiple heart cycles in order to 
accurately obtain the mean TMPG.2 In patients with RMS, a mean TMPG of <5 mm Hg is suggestive of 
mild MS while a mean TMPG >10 mm Hg supports the diagnosis of severe MS.49 Because of lack of a 
standardized definition and grading algorithm for DMS, Doppler-derived mean TMPG has commonly 
been used as the only criterion to grade MS in the epidemiologic studies in these patients.56, 57 Although 
the TMPG can be accurately measured with Doppler, several limitations impair its reliability as a marker 
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or severity of MS. The TMPG is highly dependent on the heart rate, flow across the MV and atrio-
ventricular compliance.49 Of note, high cardiac output states and significant MR can increase the TMPG.   
Other Echocardiographic Parameters 
 Enlarged LA and increased PA pressure are the major consequences of MS and increased TMPG. 
And concomitant severe pulmonary hypertension (resting PA systolic pressure >60 mm Hg) have been 
demonstrated to be a predictor of poor prognosis in patients with RMS.77 Careful evaluation of LA 
volume and PA systolic pressure is essential in assessment of MS. DMS predominantly affects elderly 
patient population with multiple comorbidities influencing LA size and PA pressure. Thus, LA 
enlargement or increased PA systolic pressure is unlikely to be specific for diagnosis of DMS when used 
alone. 
Stress Echocardiography 
The current guidelines recommend hemodynamic exercise testing with Doppler 
echocardiography or invasive hemodynamic measurements to determine exercise response of mean 
TMPG and PA pressure in patients with MS whose clinical signs or symptoms don’t correlate with resting 
Doppler echocardiography measurements.5 In simple term, two potential case scenarios which can 
benefit from evaluation of MS with stress echocardiography are; 1) asymptomatic patients with 
echocardiography findings of severe MS or 2) symptomatic patients with echocardiography findings of 
only mild/moderate MS. 
It has long been known from the invasive hemodynamics studies (mainly by Gorlin et al.) that 
exercise leads to elevated LA and PA pressures in patients with MS because of fixed MV orifice despite 
increased cardiac output.78 Studies using Doppler echocardiography have also demonstrated that mean 
and peak TMPG and PA systolic pressure significantly increase with exercise in patients with MS.79 
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Dobutamine stress echocardiography has also been confirmed as an effective and safe modality for 
assessment of severity of RMS.80 Reis et al. found that a TMPG cut-off value of ≥ 18 mmHg during 
exercise is a predictor of future adverse clinical events in patients with RMS.80  
Because exercise is more physiologic, it is the recommended way of stress for evaluation of MS.5 
It is not uncommon that patients with VHD report no symptoms because of intentional or unintentional 
limitation of activities. Exercise stress testing may help with determining the functional capacity and 
exercise induced symptoms in patients with MS. A prospective study revealed that almost 50% of 
individuals with MS (MVA ≤ 1.5 cm2) who claim to be asymptomatic with daily activities would develop 
dyspnea during a stress test.81 
Contrary to the previous guidelines,82 current VHD guidelines do not include PA systolic pressure 
(peak exercise) as a criterion for diagnosis of severe MS. However a rise in PA systolic pressure to >60 
mmHg to 70 mmHg with exercise should warrant more detailed evaluation for MS.5 Serial evaluation of 
PA systolic pressure during exercise carries importance as well. Brochet et al. demonstrated that the 
rapid and high progression of TMPG and PA systolic pressure at early exercise (compared to peak) is a 
strong predictor of dyspnea during a stress test in patients with MS.81 Conversely, PA systolic pressures 
at peak exercise was not a predictor of exercise limiting symptoms. 
It should be noted that, previous studies on use of stress echocardiography in MS have been 
performed on patients with RMS or non-specified MS. Therefore, we are still in need of further research 
to determine the utility of exercise or dobutamine stress echocardiography in evaluation of DMS. 
Although supportive evidence is still lacking, stress echocardiography may provide significant help in 
approach to patients with DMS, especially if there is discordance between symptoms and resting 
echocardiography findings. In addition, cardiopulmonary stress testing can provide further help in non-
invasive determination of the mechanisms underlying exercise intolerance in patients with DMS. The 
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clinical utility of this combined stress echocardiography and cardiopulmonary stress testing approach 
was recently demonstrated in a group of patients with RMS.83     
CONCLUSIONS AND CLINICAL PERSPECTIVES 
DMS is characterized by decreased MV orifice area and increased TMPG due to chronic non-
inflammatory degeneration and subsequent calcification of the fibrous mitral annulus and the MV 
leaflets. DMS has been a challenge for clinicians from diagnostic and therapeutic perspectives. And it has 
received limited attention from researchers up until recent years. Thus, the natural course of DMS is still 
poorly understood. 
The ‘true’ prevalence of DMS in the general population is not well. DMS predominantly affects 
the elderly individuals. It is seen in younger individuals in the setting of ESRD. Radiation induced MS 
resembles DMS and may occur >20 years after thoracic radiation exposure. Recent studies utilizing 
multimodality imaging techniques have broadened the understanding on MV function and the 
underlying mechanisms of DMS. Furthermore, recent advances in transcatheter valve interventions have 
brought hope for more effective and possibly less risky options for treatment of DMS. 
Echocardiography is the primary imaging modality for evaluation of DMS and related 
hemodynamic abnormalities such as increased TMPG and PA pressure. Classic echocardiographic 
techniques used for evaluation of MS (PHT, PISA, Continuity equation, MVA planimetry) lack validation 
for DMS. Direct planimetry with 3D echocardiography and color flow Doppler is a reasonable technique 
for determining MVA in DMS.  
Cardiac CT is superior to echocardiography in evaluation of MAC. It can be very helpful for 
evaluation of DMS, especially in the planning stages of future MV interventions. Stress 
echocardiography, preferably with exercise, may be considered in evaluation of patients with DMS 
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especially when echocardiography findings are equivocal or discordant with symptoms. Concomitant use 
of cardiopulmonary stress testing may provide further valuable information regarding the mechanisms 
underlying exercise intolerance in patients with DMS.  
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FIGURE/TABLE LEGENDS 
Figure 1:  
Title: Degenerative mitral stenosis and transcatheter mitral valve replacement. 
Caption: TEE views of a 56 year-old male with h/o ESRD, cirrhosis, CAD and HTN who presented with 
exertional dyspnea. 3D zoom view of the MV shows severe MAC sparing the leaflets (A). 3D Planimetry 
of MV revealed an area of 1 cm2 (B). Peak and mean TMPG was 11 to 13 mmHg at a heart rate of 85 
beats per minute (C). Simultaneous right and left heart catheterization demonstrated a mean TMPG of 
14 mmHg at a heart rate of 90 beats per minute (image not shown). He was diagnosed with severe DMS. 
He successfully underwent TMVR with balloon-expandable Sapien 3 (26 mm; Edwards Life Sciences, 
Irvine, CA) valve with a transapical approach (D). 
Figure 2:  
Title: Saddle shaped mitral annulus.  
Caption: Three-dimensional illustration of the mitral annulus from left antero-lateral (2-A) and anterior 
(2-B) views. A, anterior annulus; AL, antero-lateral; Ao, aortic valve; P, posterior annulus; PM, postero-
medial; TPM, tips of papillary muscles. 3D image was reconstructed by the mitral valve quantification 
software of Phillips. Revised reprint, with permission, from Garbi et al.13 
Figure 3: 
Title: Echocardiography of mitral annular calcification.  
Caption: (A) Parasternal long axis view demonstrating a bar of calcium seen in the posterior mitral 
annulus (arrow) with flow acceleration across the mitral valve. (B) Crescent shaped appearance of the 
posterior mitral annulus with severe calcification (arrow) in the parasternal short axis view. The anterior 
annulus is not seen in this view. (C) Apical four chamber view showing anterior and posterior mitral 
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annular calcification (arrow heads). (D) CW Doppler of mitral inflow showing a mean TMPG of 12 mmHg 
at a heart rate of 76 beats per minute. 
Figure 4: 
Title: Cardiac computed tomography of mitral annulus calcification. 
Caption: (2-A) Dense calcification of the anterior and posterior mitral annulus on coronal section. (2-B) 
Dense circular mitral annular calcification on oblique axial view. Mitral annular area is calculated as 4.0 
cm2. 
Figure 5: 
Caption: Survival in degenerative mitral stenosis 
Title: Kaplan-Meier survival curves of patients with mild, moderate or severe degenerative mitral 
stenosis compared with expected survival of age- and sex-matched population from US. Revised reprint, 
with permission, from Pasca et al.56 
Table 1:  
Title: Stages of Mitral Stenosis 
Caption: Adapted from the 2014 American Heart Association / American College of Cardiology valvular 
heart disease guideline.5 LA, left atrium; MVA, mitral valve area; MS, mitral stenosis; PA, pulmonary 
artery. 
Table 2:  
Title: Echocardiographic techniques for quantification of severity of DMS. 
Caption: CW, continuous wave; DMS, degenerative mitral stenosis; LVOT, left ventricular outflow tract; 
PISA, proximal isovelocity surface area; PW, pulse wave; RMS, rheumatic mitral stenosis; RVOT, right 
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ventricular outflow tract; TMPG, transmitral pressure gradient; 2D, two-dimensional; 3D, three-
dimensional. 
Table 3: 
Title: Echocardiographic signs for degenerative mitral stenosis. 
Caption: MAC, mitral annular calcification, MV, mitral valve.  
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Stage Definition Mitral Valve Area 
Hemodynamic 
Consequences Symptoms 
A At risk of MS  MVA > 1.5 cm2 
 Normal transmitral flow 
velocities 
 Normal PA pressures at 
rest 
 Normal LA volumes 
 None 
B Progressive 
MS 
 MVA > 1.5 cm2 
 ↑ transmitral flow 
velocities 
 Normal PA pressures at 
rest 
 Mild-to-moderate LA 
enlargement 
 None 
C Asymptomatic 
Severe MS 
 MVA ≤ 1.5 cm2 
 MVA ≤ 1.0 cm2 (very 
severe MS) 
 ↑ transmitral flow 
velocities 
 PA systolic pressure > 
30 mm Hg 
 Severe LA enlargement 
 None 
D Symptomatic 
Severe MS 
 MVA ≤ 1.5 cm2 
 MVA ≤ 1.0 cm2 (very 
severe MS) 
 ↑ transmitral flow 
velocities 
 PA systolic pressure > 
30 mm Hg 
 Severe LA enlargement 
 ↓ exercise 
tolerance 
 Exertional 
dyspnea 
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Echocardio
graphic  
Modality 
Tomograph
ic View 
Strengths  Limitations 
Applicabili
ty 
2D 
Plani
metry 
2D 
echocardiogra
phy 
Parasternal 
short-axis 
Not affected by;   
• Level of 
transmi
tral 
flow  
• Atrioventr
icular 
compli
ance 
• Concomit
ant 
aortic 
or 
mitral 
regurgi
tation 
• Acoustic 
shado
wing 
from 
calcific
ation 
of 
aortic 
valve, 
aortic 
root or 
mitral 
annulu
s. 
• Inability to 
visualiz
e flow 
limiting 
orifice 
• Not 
us
ef
ul 
in 
D
M
S 
be
ca
us
e 
of 
its 
li
mi
ta
ti
on
s 
3D 
Plani
metry 
3D 
echocardiogra
phy with color 
flow Doppler 
N/A 
• More 
accurat
e 
visualiz
ation 
of the 
flow 
limiting 
orifice 
• Requires 
experti
se 
• Can 
be 
us
ef
ul 
in 
ev
al
ua
ti
on 
of 
D
M
S 
• Not 
va
lid
at
ed 
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wi
th 
“g
ol
d-
st
an
da
rd
” 
m
et
ho
ds 
Pressu
re Half 
Time 
CW Doppler Apical four 
chamber 
• Easy to 
obtain 
and 
less 
time 
consu
ming 
Affected by; 
• Atrioventr
icular 
compli
ance 
• Atrial 
fibrillat
ion or 
tachyc
ardia 
• Concomit
ant 
aortic 
regurgi
tation 
or 
stenosi
s 
• Not 
re
lia
bl
e 
in 
D
M
S 
be
ca
us
e 
of 
hi
gh 
ris
k 
of 
in
ac
cu
ra
te 
es
ti
m
ati
on 
of 
M
V
A 
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PISA 
Meth
od 
• Color 
Dop
pler 
• CW 
Dop
pler 
• 2D 
ech
oca
rdio
gra
phy 
Apical four 
chamber 
Not or minimally 
affected by; 
• Mitral or 
aortic 
regurgi
tation  
• Atrial 
fibrillat
ion 
• Atrioventr
icular 
compli
ance 
• Technicall
y 
difficult 
• Time 
consu
ming 
• Risk of 
manual 
measur
ement 
errors 
• Validi
ty 
is 
un
kn
o
w
n 
in 
D
M
S 
Contin
uity 
Equati
on 
PW Doppler 
CW Doppler 
• Apical 
fou
r 
cha
mb
er 
vie
w 
for 
the 
mit
ral 
infl
ow  
• Differ
ent 
vie
ws 
for 
LV
OT 
or 
RV
OT 
str
ok
e 
vol
um
es 
• Easy to 
obtain 
Unreliable in the 
setting of; 
• Mitral 
regurgi
tation 
• Aortic or 
pulmo
nary 
regurgi
tation 
(for 
LVOT 
or 
RVOT 
stroke 
volume
s, 
respect
ively) 
• Atrial 
fibrillat
ion 
Risk of; 
• Manual 
measur
ement 
errors 
• Not 
re
lia
bl
e 
be
ca
us
e 
of 
its 
li
mi
ta
ti
on
s 
an
d 
hi
gh 
ris
k 
of 
m
ea
su
re
m
en
t 
er
ro
rs 
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Doppl
er-
derive
d 
Mean 
TMPG 
CW Doppler Parasternal 
four chamber 
• Easy to 
obtain 
• Good 
correla
tion 
with 
invasiv
ely 
obtain
ed 
gradien
ts (in 
patient
s with 
RMS) 
Affected by; 
• Heart rate 
• Level of 
transmi
tral 
flow 
and 
mitral 
regurgi
tation 
• Atrioventr
icular 
compli
ance 
• Can 
be 
us
ef
ul 
as 
a 
sc
re
en
in
g 
or 
co
nfi
r
m
at
or
y 
pa
ra
m
et
er 
 
 
 
 
 
 
 
 
 
44 
 
 
 
  Moderate or severe MAC 
  Calcification protrusion beyond mitral annulus 
  Calcification of MV leaflet(s) 
  Restricted motion or decreased opening angle of    
  MV leaflet(s) 
  Concomitant anterior and posterior MAC 
  Increased transmitral pressure gradient  
  Turbulent transmitral flow on color flow Doppler 
  Left atrial enlargement  
  Elevated pulmonary artery systolic pressure 
 
